New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 6, 2014
07:49 EDTXON, OGENOragenics advancing towards identification of lead antibiotic clinical candidate
Oragenics (OGEN) announced that through its Exclusive Channel Collaboration with Intrexon Corporation (XON), it has produced and analyzed a large number of new potential analogs generated from its Mutacin 1140 antibiotic program platform, and advanced several promising compounds for further evaluation. These compounds will serve as the basis for selecting a lead drug candidate for clinical development later this year. The triaged analogs were selected from hundreds of variants generated using genetic engineering at Intrexon. Dr. John N. Bonfiglio, CEO of Oragenics, remarked, "The compounds we have selected for final evaluation align with our goal of identifying the first lead compound this year. We plan on meeting with the FDA later this year to discuss the IND enabling activities necessary to submit an IND application by mid-2015. Intrexon’s synthetic biology expertise in collaboration with our scientists has enabled generation of a large library of new potential MU1140 analogs with chemical and biological properties that differentiate from native MU1140. We remain very optimistic that these new lantibiotics will become useful in the fight against certain drug-resistant bacteria.”
News For OGEN;XON From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 9, 2015
16:24 EDTOGEN, XONOragenics, Intrexon terminate Channel Collaboration Agreement
Subscribe for More Information
September 30, 2015
10:36 EDTXONOptions with increasing implied volatility
Subscribe for More Information
September 29, 2015
10:48 EDTXONOptions with increasing implied volatility
Subscribe for More Information
08:17 EDTOGENOragenics announces completion of independent ProBiora3 study
Oragenics announced the completion of an independent study evaluating the effects of a chewable tablet containing ProBiora3, in early childhood development of dental caries in preschool children living in low socioeconomic, multicultural areas. The study was conducted under the guidance of Professor Svante Twetman, a probiotics expert, with the results published in a peer reviewed journal. The study employed a randomized double-blind placebo-controlled design consisting of 138 healthy children ranging from two to three years in age. The children were placed into groups that were administered once a day either chewable tablets containing ProBiora3 or a placebo tablet. In conjunction with this study, parents were further instructed to thoroughly brush the children's teeth in each group twice daily with fluoride toothpaste. Study duration was one year with 66% compliance. Overall, the ProBiora3 administered group observed statistically significant lower dental caries increments than in the placebo group, 0.2 vs. 0.8. The risk reduction for caries development was 0.47, with no side effects being reported among either group.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use